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ABSTRACT: 
In order to address outstanding questions about ruthenium complexes in complex 
biological solutions, 19F NMR spectroscopy was used to follow the binding preferences 
between fluorinated RuII(h6-arene)(bipyridine) complexes and protected amino acids and 
glutathione. Reporting what ruthenium compounds bind to in complex environments has 
so far been restricted to relatively qualitative methods, such as mass spectrometry and X-
ray spectroscopic methods; however, quantitative information on the species present in 
the solution phase cannot be inferred from these techniques. Furthermore, using 1H NMR, 
in water, to distinguish and monitor a number of different complex RuII(h6-arene) adducts 
forming is challenging. Incorporating an NMR active heteroatom into ruthenium 
organometallic complexes provides a quantitative, diagnostic ‘fingerprint’ to track solution-
phase behaviour and allow for unambiguous assignment of any given adduct.  The 
resulting 19F NMR spectra show for the first time the varied, dynamic behaviour of 
organoruthenium compounds when exposed to simple biomolecules in complex mixtures. 
The rates of formation of the different observed species are dramatically influenced by the 
electronic properties at the metal, even in a closely related series of complexes in which 
only the electron-donating properties of the arene ligand are altered. Preference for 
cysteine binding is absolute: the first quantitative solution-phase evidence of such 
behaviour. 
INTRODUCTION: 
One motivation for using ruthenium in medicinal compounds is to introduce a drug-target 
interaction for which the bonding energy is between that of true non-covalent 
intermolecular interactions and a covalent bond.1–3 In principle, tuning the strength of a 
metal-target coordination bond could be used to control the dissociation rate of a drug-
target interaction in a way that is orthogonal to that provided by conventional medicinal 
chemistry. Consequently, a raft of studies have begun to explore the binding preferences 
of simple ruthenium organometallic complexes for biomolecular targets, with many of 
these compounds demonstrating promising anticancer activity.4–6  
The ruthenium complexes that have entered clinical trials, NAMI-A and KP1019 have 
received significant attention with respect to their distributions within plasma and in cells. 
They are characterized by having a number of ligands we would class as exchangeable in 
aqueous solution on a timescale relevant to cellular processes. These complexes are very 
promiscuous in complex biological mixtures, with little understanding of their modes of 
action or final cellular speciation.7–9  
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Ruthenium(II) arene complexes incorporating a wide range of different ligands have also 
been studied extensively in this context.10–16 In comparison with RuIII complexes, the 
RuII(h6-arene) bioactive scaffold has led to increased control over the biomolecular targets 
of ruthenium complexes. RAPTA-type complexes, [Ru(arene)(PTA)X2] preferentially bind 
to proteins17,18whereas RAED-type complexes [Ru(arene)(en)Cl] (en = 1,2-
ethylenediamine) preferentially bind to DNA; this binding can be enhanced through 
extended p-systems.19,20 Although these complexes have shown promising anticancer 
activity, they are still highly promiscuous and there is little insight into their complete 
cellular speciation. 
The dynamic nature of the cellular concentrations and accessibility of biomolecules 
combined with the characteristically slow ligand exchange rates associated with Ru(II) 
arene complexes,21 makes understanding the relationship between speciation of the metal 
complexes and cellular response problematic. A direct read out of what the ruthenium 
compounds are bound to in biological environments remains challenging  and has so far 
been restricted to relatively qualitative methods, such as mass spectrometry22–24 and X-ray 
spectroscopic methods.25–27  
NMR spectroscopy is a quantitative, sensitive, direct reporter for solution behaviour. 
However, using 1-Dimensional 1H NMR to follow the speciation of ruthenium complexes 
has proved testing for anything other than the simplest examples. The large number of 
observable proton signals together with their chemical similarity and hence proximity in the 
spectra severely restricts the usefulness of 1H NMR in this context. 2-Dimensional NMR 
experiments can overcome this complexity; however, these experiments are often time 
consuming, with high sample concentration necessary, if temporal resolution is required. 
31P NMR has been used extensively for following the metabolic state of phosphate esters 
in vivo.28–30 15N and 13C are commonly used to examine the structure and dynamics of 
proteins in vivo.31  
19F NMR can also be used as a sensitive probe of specific metabolic signals when a 
fluorine atom can be incorporated into a small or large biomolecule as a reporter.32,33 The 
use of ligand-based fluorine NMR screening methods to rapidly identify biologically active 
fluorinated organic compounds has demonstrated the usefulness of being able to detect a 
19F NMR signal in complex environments.34,35  
Furthermore, incorporating fluorine atoms into lead drug compounds, has proven to be a 
popular way to improve the pharmacological properties of organic-based drugs, with 
approximately 20% of all currently available drugs on the market containing at least one 
fluorine atom.34 Recently, a fluoride ligand has been incorporated into the axial position of 
a Pt(IV) anticancer pro-drug to enhance stability and cytotoxicity.36 Therefore, we believe 
that incorporating fluorine substituents into RuII arene complexes can be greatly beneficial 
in probing their reactivity in complex mixtures, as well as a means of altering activity. 
Throughout this study, we have used 19F NMR to gather quantitative information, such as 
kinetic parameters and percentage formation of the species present in solution, with mass 
spectrometry used to support the assignment of species. This combined approach can 
greatly simplify observing the binding preferences of Ru(II) arene in complex biological 
mixtures. The purpose here, was not to develop a new bioactive ruthenium organometallic 
compounds, but to explore a quantitative spectroscopic method for quickly and accurately 
assigning the speciation of ruthenium organometallics in complex solutions.    
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Table 1: Complexes synthesized and studied in this work, isolated and used as the 
hexafluorophosphate salts. 
Incorporating the fluorine atoms into a bipyridyl ligand, which is stable to dissociation, 
enabled at least two fluorines in chemically similar environments to be introduced to each 
complex. We synthesised four fluorinated 2,2’-bipyridyl derivatives; 3,3’, 5,5’, 6,6’-difluoro 
and 5,5’-trifluoromethyl. To counteract the electron withdrawing effect of the fluorinated 
ligands on the metal, we also varied the arene ligand, including more electron-donating 
substituted arenes by way of compensation. The full set of complexes reported is listed in 
Table 1, and Figure S1.   
Some of these complexes provide excellent sensitivity to the metal coordination 
environment and dispersion of signals that have allowed us to resolve the surprising 
number of different species present. The sensitivity we report suggests that this approach 
could be developed for use in vivo and we have made attempts to test that. We also show 
that the rates of formation of different species are dramatically influenced by the electronic 
properties at the metal, even in a closely related series of complexes in which only the 
electron-donating properties of the arene ligand are altered. 
RESULTS AND DISCUSSION 
A number of literature preparations are available for the preparation of functionalised 
bipyridines,37,38 however, after achieving relatively poor yields using copper catalysed, 
Ullman-type coupling reactions, the fluorinated bipyridines were synthesised using an 
adapted palladium-catalysed homocoupling procedure in poly(ethylene) glycol (see 
Experimental Section).39 We found that all except the 4,4’-difluorobipyridyl derivative could 
be made reliably in good yield; we have not pursued the 4,4’ derivative any further. The 
synthesis of the ruthenium complexes [1] – [12] was achieved by reacting the appropriate 
ruthenium arene dimer with a stoichiometric amount of the chosen bipyridyl derivative. 
These complexes were characterised by NMR, ESI-MS, elemental analysis and X-ray 
diffraction.  
Single crystals suitable for X-ray diffraction for complexes [1] – [10] were grown via slow 
diffusion of diethyl ether into a saturated solution of the complex in acetone. The X-ray 
crystallographic data for all complexes are given in Tables S2-4. The novel complexes [1]- 
[10] adopt a pseudo-octahedral piano stool configuration. A representative analysis of key 
bond lengths and angles for the 5,5’-fluorinated bipyridine series is summarised in Table 
S1. Complexes [1] and [2] have shorter Ru-Cl bond lengths than complexes [3] and [4] 
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which could provide a hint towards the lability of the chloride when other nucleophiles are 
present, but these small differences cannot be used to inform solution based behavior.   
Speciation in Aqueous Solutions  
Before exposing the ruthenium complexes to biomolecules, they were monitored in 
deuterated phosphate buffer, pD = 7.2 and 1% DMF which leads to an equilibrium 
between chloro, aquo and phosphate adducts, Figure 1a. In order to be able to see as 
many relevant species as possible, high concentrations of the complexes under study 
were needed so a small amount of DMF was used, to enhance solubility. We have seen 
no evidence of DMF coordinating under these conditions. For the fluorinated complexes 
[1] - [8] and [10], three singlet peaks are observed in the 19F NMR spectra, as represented 
in Figure 1b. The behaviour of complex [9], the 6,6’-bipyridyl derivative, was significantly 
different suggesting that the proximity of the fluorines to the metal impacted upon the 
ligand exchange properties. For [11]-[12], 1H NMR spectra were used to resolve the 
speciation through the diagnostic metal-coordinated arene signals.40  
Figure 1: Figure 1a: The equilibria that exist when [Ru(h6-arene)(5,5’-difluorobipyridine)]+ 
complexes are incubated in phosphate buffer. Figure 1b: Time course 19F{1H} NMR 
spectra of complex [4] incubated in 10mM deuterated phosphate buffer (2 mM Ru, pD = 
7.2, 310 K). After 24 hr, 1 eq. of AgNO3 was added to abstract the chloride ligand and 
encourage formation of the aquo complex. Figure 1c: 19F{1H} NMR spectra of complex [2] 
incubated in D2O and buffered D2O of different phosphate concentration (2 mM Ru, pD = 
7.2 (when buffered), 2 hr, 310 K). Figure 1d: Mass spectra recorded of the solution mixture 
when complex [2] is incubated in D2O and buffered D2O, expected masses quoted in 
Table S6.  
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With a number of titratable groups involved in these systems, examining the ligand 
exchange behaviour of these complexes around conditions of pH relevant to biological 
conditions requires strong buffering. We chose phosphate as a buffer also for its relevance 
to biological conditions. However, it is clear that phosphate competes quite strongly as a 
ligand to the metal , Figure 1c, and the presence of phosphate species have been 
confirmed by mass spectrometry, Figure 1d and Table S6. Sadler et al. showed that the 
structurally related [Ru(h6-arene)(en)Cl]+ initially binds to the phosphate in the nucleobase 
5-GMP before being displaced by the guanine N7.41 To maintain a balance between 
buffering strength and introducing a competing ligand a phosphate buffer concentration of 
10 mM was chosen for all incubations, when the ruthenium concentration was 2 mM.  
19F resonances from the aquo and phosphate species are pH dependent and therefore the 
pKa for the deprotonation of the bound aquo ligand can easily be measured. Figures 2a, 
2b and 2c show representative data and calculated pKa values for the benzene complexes 
with different bipyridyls (Complexes [1], [10] and [11]) and for the 5,5 difluorobipyridyl 
complex with different arene ligands (Complexes [1] – [4]). The observed differences in 
pKa are entirely consistent with the changes in electron density at the metal due to the 
subtleties of the electron withdrawing effects of fluorines on the bipyridyl ligand and the 
electron donating effects of the different arenes.42 In other words, the trend observed 
going from complex [1] – [4] shows that the increasing electron donating capability of the 
h6-arene ligand to the ruthenium centre leads to a higher measured pKa value; an 
increased electron density on the metal lowers its Lewis acidity. The electron withdrawing 
capabilities of the trifluoromethyl group on complex [10] significantly increases the Lewis 
acidity, reflected in the lowest pKa measured for any of these complexes. Interestingly, 
pKa had to be measured using 1H spectra because the 19F resonances in this complex, 
where the fluorine atoms are not directly on the bipyridyl ring, are not sensitive enough to 
changes in coordination to accurately measure the pKa. Clearly this has implications for 
the general use of 19F on spectator ligands for reporting changes at the metal site.  
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Figure 2a: pH dependence of the chemical shifts of the aquo coordinated ruthenium 
species and determination of the pKa in the following complexes [1] - Red circles; [2] - Blue 
squares; [3] - Pink triangles; [4] - black circles; [10] - Green squares; [11] - Orange 
triangles. 19F chemical shifts of the 5,5’-difluorobipyridyl fluorines or 1H chemical shift of 
the coordinated benzene ligand were plotted against pD. The lines are a least squares fit 
to an equation involving a single titratable group. Figure 2b: A series of 19F{1H} decoupled 
spectra of complex [1] in D2O phosphate buffer at differing pD values (2 mM Ru, 298 K). 
Figure 2c: The pKa values of a series of ruthenium complexes measured using (where 
applicable) both 19F{1H} NMR and 1H NMR. (a) – Unable to measure pKa from data 
collected. (b) – No fluorine atoms present in complex. 
Diagnostic determination of amino acid binding  
Reaction of these probes with N- and/or C-protected amino acids gave a series of 
characteristic 19F NMR signals, allowing for unambiguous assignment of any given adduct. 
We note that the fluorines on the bipyridyl ring are diastereotopic and once a chiral amino 
acid ligand is coordinated to a ruthenium in the piano stool complex they are magnetically 
inequivalent.43 Therefore, despite the symmetry of the starting molecule, the amino acid 
coordinated adducts of these complexes don’t always give rise to single resonances in the 
proton decoupled 19F NMR spectra. 
It is therefore necessary to point out how we have interpreted the spectra and especially 
how the diastereotopic context of the fluorine atoms in the 5,5’-bipyridyl positions results in 
more complex 19F NMR spectra than one might expect. For instance, when complex [1] is 
incubated with N-acetyl L-glutamine two doublets separated by 0.18ppm are observed, 
which we attribute to one species with the glutamine coordinated via the a-carboxylate of 
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the amino acid.  That these signals originate from the same species is clearly evidenced 
by the 8JF-F coupling of 2.26 Hz observed at high resolution and a clear cross-peak in a 
proton decoupled 19F-19F COSY experiment (Figure 3). When achiral amino acids (e.g. N-
acetyl glycine) are coordinated through the a-carboxylate only a singlet is observed, as 
expected (Figure S2). 
Figure 3: A 19F{1H} - 19F{1H} COSY spectra from the incubation of complex [1] with N-
acetyl L-glutamine (2 mM Ru, 3 eq. amino acid, starting pD = 7.2, 24 hr, 310 K). 
Under similar conditions, a ruthenium species with N-acetyl cysteine methyl ester 
coordinated can also give more than one peak (see Figure 4, complexes [1] (Ar = 
benzene) and [3] (Ar = p-cymene). In the case of complex [1], variable temperature 
experiments show that this really is two coupled doublets with very strong roofing (Figure 
S3). The chemical shift separation between the diastereotopic fluorine signals is small and 
consequently this peak often appears as one broad resonance. Again, achiral thiolate 
molecules (cystamine for instance) clearly coordinate through the sulfur and yield a sharp 
singlet in the proton decoupled 19F{1H} spectrum (Figure S2). Additionally, the variable 
temperature experiments provided no indication that there is restricted rotation about the 
metal ligand bond that could cause an environment that breaks the symmetry (Figure S3). 
However, the consequences of the diastereotopic fluorines are not always manifest in the 
spectra. In the case of the 3,3’-difluorobipyridyl complexes, [5] (Ar = benzene) and [7] (Ar = 
p-cymene), only one Ru-cysteine 19F NMR signal is observed, see Figure 4. The crystal 
structure of the 3,3’-difluorobipyridyl containing complex, [5], shows that the organometallic 
ion is in fact chiral at the metal due to the adjacent fluorines being forced out of plane by 
each other (both enantiomers are present in the centrosymmetric crystal structure, see 
ESI). Should a chiral amino acid coordinate in place of the chloride, this would technically 
generate diastereomers. Presumably the metal-ligand coordination sphere is flexible 
enough in solution for there to be fluxionality between the two non-planar pyridyl rings 
such that the two fluorine environments appear equivalent and we observe only one 19F 
NMR signal, the non-chiral average. So, although coordination of the 3,3’-
difluorobipyridine ligand to the ruthenium piano stool should also lead to diastereotopic 
fluorines, they appear in the same magnetic environment and their signals do not split into 
two. 
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Figure 4: A series of 19F{1H} NMR spectra of complexes [1], [3], [5] and [7] incubated with 
N-acetyl cysteine methyl ester (2 mM Ru, 3 eq. amino acid, 310 K). The chemical shift 
scale is the same for all spectra, which are aligned to the chloride peak in each case. 
Absolute d values given in Table S5. 
The extra complexity in the signals observed with the fluorines in the 5,5’-bipyridyl 
positions reduces the sensitivity of the experiment given that we generate two 19F signals 
for each amino-acid coordinated ruthenium complex rather than one intense singlet. 
However, the sophistication in the level of detail we can observe with this technique is 
exemplified where the diastereotopic nature of the fluorines is apparent in the spectra.  
Therefore, we pursued the 5,5’-difluorobipyridyl complexes to give us the most complete 
understanding of the complexes under discussion but noting that the 3,3'-difluorobipyridine 
complexes might be more suited to further studies of more complex mixtures of species.  
Influence of the arene ligand on complex speciation  
The 19F NMR spectra of the 5,5’-difluorobipyridyl complexes [1] - [4] incubated with N-
acetyl cysteine methyl ester, Figure 5, show the extent to which ligand exchange varies 
with different arene ligands. In addition, the electron donating properties of the arene 
ligand influence the chemical shift separation of the doublets with the hexamethylbenzene 
complex, [4] providing the greatest resolution. 
Figure 5: 19F{1H} NMR spectra of complexes [1], [2], [3] and [4] incubated with N-acetyl 
cysteine methyl ester (2 mM Ru, 3 eq. amino acid, 24 hr, 310 K). The chemical shift scale 
is the same for all spectra, which are aligned to the chloride peak in each case. Absolute d 
values given in Table S5. 
The formation of the ruthenium cysteine adducts have been measured over a short period 
and rate constants measured, Table 2 and Figure S4. There is an initial rapid approach to 
equilibrium between the chloride, aquo and phosphate species. The observed rate of 
cysteine complex formation is adequately described by a 1st order process, therefore, we 
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believe ligand dissociation to be the rate determining step. The benzene and tolyl 
complexes, [1] and [2] have comparable rate constants, however, the cymene and 
hexamethylbenzene complexes [3] and [4] are slightly faster, as expected, due to the 
increased electron donating capabilities of the cymene and hexamethylbenzene ligands.  
Table 2: A comparison of the rate constants for the complexes [1] – [4] for the formation of 
a ruthenium cysteine adduct (2mM Ru, 3 eq amino acid, 310 K)  
A screen of complex [1] with all of the naturally-occurring amino acids with side chains 
suitable for metal coordination allowed us to identify those amino acids (cysteine, glutamic 
acid, histidine and methionine) that give detectable metal complexes at relatively low 
adduct concentrations. These amino acids were protected at both the amino and 
carboxylate ends, to limit binding to amino acid side chains, and incubated in an excess of 
the ruthenium complexes [1] - [4]. The chosen amino acids offer some side chain variety 
given that we predicted that cysteine and methionine would coordinate through sulphur, 
glutamic acid through oxygen and histidine through nitrogen.  
These incubations were followed by 19F{1H} and 1H NMR, and mass spectrometry (Table 
S7) over a 24-hour period at 310 K in 10 mM D2O phosphate buffer with starting pD = 7.2. 
These temporal experiments enabled us to identify and quantify signals due to ruthenium-
amino acids adducts, e.g. complex [1] with cysteine, Figure S5. The data from these 
incubations is summarised in Table 3 for the two electronic extremes, the benzene arene, 
complex [1], and the hexamethylbenzene arene, complex [4]. Given that the coordination 
of some amino acid side chains results in a release of protons it proved difficult to clamp 
the pD tightly in the experiments described below, even with 10 mM phosphate buffer. The 
exact change in pD of any experiments described below could be measured intrinsically 
from the chemical shift of the 19F signals from each specific aquo complex, which are 
exceptionally sensitive to changes in pD. The greatest adduct formation is observed for 
both complexes [1] and [4] with N-Ac-Cysteine-OMe. Furthermore, the adduct formation 
with [4] is much greater for the softer side chains of cysteine, histidine and methionine.  
Table 3: Reactions of complexes [1] and [4] with protected amino acids (2 mM Ru, 1.5 eq. 
amino acid, buffer starting pD = 7.2, 310 K). % reaction is calculated through integrating 
[Ru]-amino acid peak with respect to the peak areas of the chloride, aquo and phosphate 
species. pD is measure from the d of the aquo species.  
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Competition experiments for amino-acid binding  
The 19F{1H} NMR spectra of complex [1] after 24 hours (where the reaction was essentially 
at equilibrium) when incubated with N-protected esters of cysteine, glutamic acid, histidine 
and methionine, are presented in Figure 6 and show metal coordination to all four, distinct 
amino acid side chains. The preference for cysteine binding is validated through a 
competition study involving a mixture of all four amino acids which confirms the first direct 
evidence for the much-asserted claim that ruthenium(II) organometallic complexes 
preferably bind to sulphur centres in a biological context. The extent of this preference is 
remarkable, especially when compared to methionine, whose thioether donor group is 
almost completely outcompeted by cysteine’s thiolate. Surprisingly, it also outcompetes 
histidine under our conditions. The difference in the chemical shift of the aquo species 
indicates that the pD after 24 hours of incubation is no longer 7.20, due to release of 
protons from amino acid coordination. This change is emphasised in these experiments 
due to the working pD being near the pKa for the ruthenium aquo species, and this does 
not distract from the key competition experiments presented in Figure 6.  
In principle, of course, one could use high-resolution, 1H NMR data to uncover the 
speciation we have demonstrated above using 19F NMR. The enhanced clarity of using 19F 
NMR to monitor speciation of ruthenium complexes in complex biological mixtures is 
demonstrated by comparing the time course 19F NMR and 1H NMR spectra when complex 
[1] is incubated with the four protected amino acids in competition as discussed above, 
Figure S6. The 19F NMR spectra allow for rapid (32 scans, 2 minute measurement) 
identification of the number and concentration of different ruthenium species in solution. 
The 1H NMR spectra are, however, difficult to deconvolute without time consuming 2-D 
NMR experiments, and peaks often overlap or are co-incident. The data in Figure S6 are 
for the best-case scenario; for complexes containing any arene ligand other than benzene, 




Figure 6: A series of 19F{1H} NMR spectra when complex [1] is incubated with the 
protected amino acids, N-Ac-Cys-OMe, N-Z-Glu-OMe, N-Bz-His-OMe, N-Ac-Met-OMe, 
and a mixture of all amino acids together, (2 mM Ru, 3 eq. each amino acid, 24 hr, 310 K).  
It is worth explaining here that the signals observed from methionine, glutamic acid and 
histidine coordinated species reveal additional layers of complexity leading to multiple 
resonances in the 19F NMR spectra. While the methionine species in Figure 6 generates 
what looks like a singlet, binding to complexes [2] – [4] gives two doublets of unequal 
intensity (Figures S7-9). Our interpretation of this is that methionine thioether coordination 
generates a new chiral centre at the sulphur and the two consequent diastereomers are 
not formed equally. For histidine coordination the diastereotopic fluorines described above 
are more obvious, but again two doublets of unequal intensity are observed and this is 
ascribed to species that differ by coordination through either of the imidazole nitrogens, Nδ 
or Nε. 
We have tried to crystallise the amino acid-coordinated complexes in many instances, but 
the only example that has yielded diffraction quality crystals is that of [Ru(h6-
benzene)(2,2’-bipyridine)(N-acetyl cysteine)][PF6], [13], synthesised from [11] in an excess 
of cysteine. There is nothing surprising about this particular structure in terms of bond 
lengths and angles. The crystal lattice is stabilised primarily by H-bonding between the 
amino acid NH and CO groups and water, together with stacking of the bipyridyl rings.  
When incubated with N-acetyl cysteine, the ruthenium complex is exposed to nucleophilic 
attack from both the a carboxylate and thiolate Lewis bases. Interestingly, temporal 
studies of these samples, show that the carboxylate coordinated species form most 
rapidly, before being replaced by the thiol coordinated species (Figure S10). The crystal 
structure reports the preference for metal-thiolate adduct formation in the solid state. The 
NMR spectroscopy and crystallographic evidence suggest that these ruthenium(II) arene 
bipyridine complexes form surprisingly stable cysteine adducts in contrast to other 
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structurally similar complexes whereby cysteine coordination appears to catalyse further 
decomposition.44–46   
Figure 7: Structure of complex [13] showing displacement ellipsoids at 50% probability. 
The counterions, hydrogen atoms and lattice water molecules have been omitted for 
clarity.  
Binding to Glutathione 
Reasoning that complex [1] would bind to cysteine in a cell if presented with the 
opportunity, we probed its reactivity with the most bioavailable source of cellular cysteine 
residues: glutathione. The cell redox buffer, glutathione, equilibrates between reduced 
monomer (GSH, containing a thiol) and oxidized dimer (GSSG, containing a S-S bridge). 
Incubating [1] with varying defined mixtures of GSH and GSSG gives 19F NMR spectra 
which quantifiably show that binding to the acid groups is preferred in the absence of free 
thiolate, but that binding to cysteine’s thiolate group is markedly thermodynamically 
preferred in the regimes for which it is available (Figure 8). Complexes [2], [3] and [4] also 
exhibit preferential thiolate coordination (Figures S11-13).  
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Figure 8: A series of 19F{1H} NMR spectra when complex [1] is incubated with defined 
mixtures of reduced and oxidised glutathione (2 mM Ru, 3 eq. glutathione, 24 hr, 310 K).  
CONCLUSIONS 
19F NMR spectroscopy has enabled us to undertake a detailed study of a suite of 
ruthenium organometallic complexes with fluoro-substituted bipyridyl ligands and their 
ligand exchange behaviour with amino acid side chains. The 19F NMR spectra provide 
quantitative information on the reactions of these complexes with amino acid Lewis bases 
which couldn’t be gathered using traditional 1-D 1H NMR (2-D experiments rely on 
extensive measurement time). Specifically, we can assess the relative binding preferences 
for each metal complex and track the speciation of the complexes on a relevant time scale. 
While our question is ultimately to ask whether these or related complexes might report 
what they are bound to in complex biological mixtures, perhaps even cellular cytoplasm, 
the complexity of signals even in relatively simple mixtures at moderate concentrations 
surprised us and this required careful and detailed analysis to ensure that the output from 
the 19F NMR could be accurately interpreted.  
Of course, the main targets for ruthenium organometallics in cells are likely to be proteins 
which can provide one or more Lewis basic sidechains at a given site to exchange with the 
metal. We will extend our 19F reporter studies to examine speciation following reaction with 
proteins, but early experiments show that this cannot be generalised for all proteins and 
results are, unsurprisingly, very protein specific. However, we believe the insight provided 
by the experiments described above are not just useful, but essential to understand 




When necessary all reactions were kept under an inert atmosphere or under a N2 flow 
using standard Schlenk line techniques. Methanol (MeOH), acetonitrile (MeCN), 
dichloromethane (DCM) and other required solvents were dried through distillation, stored 
over suitable drying agents and purged with N2 before use.  
Chemicals and Reagents 
Chemicals and solvents were purchased from chemical suppliers Sigma-Aldrich, Merck, 
Acros Organic and Insight Biotechnologies.  
Physical Measurements 
Mass spectrometry was performed on a Micromass Quattro LC ESI-mass spectrometer. 
Samples were typically prepared in ultrapure water or 50:50 ultrapure water/acetonitrile. 
Ionization was achieved with a capillary voltage of 2.8 kV, cone voltage of 30 V and a 
collection voltage of 3 V. Desolvation and capillary temperatures were 323 K. 
Single-crystal X-ray diffraction data were collected at 180 K using either a Nonius 
KappaCCD or Bruker D8-QUEST diffractometer, equipped with MoKa or CuKa radiation, 
respectively. Structures were solved using SHELXT47 and refined on F2 using SHELXL.48 
1H, 13C, 19F and two-dimensional NMR spectra were collected using a 400 MHz Bruker 
Avance III. 1H NMR spectra were collected at 400.13 MHz, 13C NMR spectra at 100.57 
MHz and 19F 376.50. All 1D 19F NMR spectra were recorded using an inverse gated 
decoupling pulse programme so that integration values can be quantified. Fluorine COSY 
experiments were collected using a 400 MHz Bruker QNP Cryoprobe spectrometer.  
Elemental (C, H, N) analyses were obtained using an Exeter CE-440 Elemental Analyser. 
Syntheses  
The detailed syntheses and characterisation of the ruthenium arene dimers, fluorinated 
bipyridine ligands (A) – (D) and ruthenium complexes [1] – [10] are presented in the 
supporting information. Representative syntheses of the fluorinated bipyridines and 
ruthenium bipyridine complexes are as follows:   
General Procedure for the synthesis of fluorinated bipyridine ligands (a) – (d).  
The starting bromopyridine (1 mol equiv), PdII(OAc)2 (0.025 mol equiv.), K2CO3 (1 mol 
equiv.) and poly(ethylene glycol) (Mw 4000, 5.0 – 10g) were combined in a nitrogen 
purged flask. This mixture was heated to 120 °C and the temperature maintained for 48 
hours with stirring. The mixture was cooled to 80 °C and 15 mL of warm water was added. 
Once at room temperature a further 10 mL of water was added and the suspension 
exhaustively extracted with ethyl acetate. The combined extracts were washed with 
saturated aqueous Na2S2O3 and three times with brine.  The organic layer was then dried 
over MgSO4 and solvent removed in vacuo. The product was then purified via sublimation. 
General Procedure for the Synthesis of Ru complexes 
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[RuCl2(h6-arene)]2 (1 mol equiv.) and (a), (b), (c) or (d) (2 mol equiv.) were added to a 
nitrogen purged flask. Freshly distilled MeOH was added and the reaction was stirred for 
24 hours at room temperature. The contents were filtered under gravity to remove 
unreacted ruthenium dimer and the solution was reduced to approximately 5mL in vacuo. 
NH4PF6 (6 mol equiv) was added and the mixture was shaken and left at -10 °C for a 
further 24 hours. The product was collected by gravity filtration as an orange/yellow solid 
and washed with cold MeOH and Et2O. Purification could be achieved through 
recrystallization from hot MeOH.  
Synthesis of [13] - [Ru(h6-benzene)(2,2’-bipyridine)(N-acetyl cysteine)][PF6] 
In a typical experiment N-Acetyl-Cysteine (21 mg, 0.12 mmol) was dissolved in water (8 
mL) and complex [8] (30 mg, 0.058 mmol) added forming a yellow solution that turned 
orange after 18 hours. The reaction mixture was stirred at 60 °C for 72 hours before being 
cooled to RT and then stored at 4 °C for 72 hours. The resulting red crystals, suitable for 
single crystal X-ray diffraction, were collected on the filter and washed with ice cold water 
(1 mL) before being dried in vacuo.  
1H NMR: (400.13 MHz, d6-DMSO): 9.09 (dd, 3JHH = 11.0 Hz, 3JHH = 5.4 Hz, 2H, 6,6’-
position), 8.33 (dd, 3JHH = 8.2 Hz, 3JHH = 6.0 Hz, 2H, 3,3’-position), 8.09 (overlapping ddd, 
3JHH = 8.2 Hz, 3JHH = 8.0 Hz, 4JHH = 5.4 Hz, 2H, 4,4’-position), 7.79 (overlapping ddd, 3JHH 
= 11.0 Hz, 3JHH = 8.0 Hz, 3JHH = 6.0 Hz, 2H, 5,5’-position),  5.95 (s, 6H, PhH), 3.74 (m; 1H 
N-Ac-Cys-C*H,), 2.12 (m; 2H; N-Ac-Cys-CH2), 1.75 (s; 3H; N-Ac-Cys-CH3).  13C{1H} NMR: 
(100.57 MHz, D2O): 174.2, 173.3 (N-Ac-Cys-CH3CONH- + N-Ac-Cys-COOH), 155.2 (6,6’-
position, 154.7 (2,2’-position), 139.5 (4,4’-position) 127.2 (5,5’-position), 123. (3,3’-
position), 88.5 (PhH), 54.7 (N-Ac-Cys-C*H), 29.2 (N-Ac-Cys-CH2), 21.4 (N-Ac-Cys-CH3,). 
IR: ν(N-H) 3648 (m); (X-H) multiple weak signals around 3000; (C=O acid) 1735 (m); (C=O 
amide) 1607 (s); (arene stretches) 1471 (m) & 1445 (s); (arene bends) 837 (s), 820 (s), 
763 (s) & 726 (m). LR-MS: (ESI+ m/z 498.0 (singly charged, [Ru(η6-benzene)(2,2’-
bipyridine)(N-acetyl-cysteine)] +).  
pKa Measurements 
10 mM deuterated phosphate buffer solution was prepared using potassium dihydrogen 
orthophosphate in D2O and adjusted to different pD values in the range of 4.7 to 11.2 
using 1N NaOD. The different buffers were then incubated with Complexes [1] – [4], [10] 
and [11] for 2 hours at 298 K and 1H and 19F{1H} NMR spectra recorded. All 19F{1H} NMR 
spectra recorded are 32 scans. pD values are corrected pH meter readings.  
Biomolecule interactions 
The incubations between ruthenium and amino acids were performed in either a 1.5 or 3 
molar excess of amino acid/ glutathione. Ruthenium complexes were dissolved in 1% DMF 
and diluted with a solution of amino acid in D2O phosphate buffer pD = 7.2.  19F{1H} NMR 
spectra were recorded at 2, 4, 8 and 24 hours, with mass spectra recorded at 8 and 24 
hours. All 19F{1H} NMR spectra recorded are 32 scans. 
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